26120-86-5

Basic information

• Product Name: 2,5-DIFLUOROBENZENESULFONYL CHLORIDE
• Synonyms: 2,5-DIFLUOROBENZENESULPHONYL CHLORIDE;2,5-DIFLUOROBENZENESULFONYL CHLORIDE;AKOS B019395;ART-CHEM-BB B019395;BUTTPARK 21\07-13;2,5-Difluorobenzenesulphonyl chloride 98%;2,5-Difluorobenzenesulphonylchloride98%;2,3-Difluorobenzenesulfonyl chloride
• CAS NO: 26120-86-5
• Molecular Formula: C₆H₃ClF₂O₂S
• Molecular Weight: 212.6
• Product Categories: Aromatic Halides (substituted);Benzenesulfonyl chloride;Organic Building Blocks;Sulfonyl Halides;Sulfur Compounds;Fluorine series
• Mol File: 26120-86-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 221 °C(lit.)
• Flash Point: >230 °F
• Appearance: Clear colorless to yellow liquid
• Density: 1.58 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0792mmHg at 25°C
• Refractive Index: n20/D 1.516(lit.)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Sensitive: Moisture Sensitive
• BRN: 2723886
• CAS DataBase Reference: 2,5-DIFLUOROBENZENESULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-DIFLUOROBENZENESULFONYL CHLORIDE(26120-86-5)
• EPA Substance Registry System: 2,5-DIFLUOROBENZENESULFONYL CHLORIDE(26120-86-5)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3265 8/PG 2
• WGK Germany: 3
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 26120-86-5(Hazardous Substances Data)

Usage

Description

2,5-Difluorobenzenesulfonyl chloride is a chemical compound that plays a crucial role in the synthesis of aryl sulfonamide-based mineralocorticoid receptor (MR) antagonists. It is characterized as a clear colorless to yellow liquid, which indicates its purity and stability in chemical reactions.

Uses

Used in Pharmaceutical Industry:
2,5-Difluorobenzenesulfonyl chloride is used as a key intermediate in the synthesis of aryl sulfonamide-based mineralocorticoid receptor (MR) antagonists. These MR antagonists are important for the development of drugs that target the mineralocorticoid receptor, which plays a significant role in various physiological processes, including fluid and electrolyte balance, blood pressure regulation, and stress response. By modulating the activity of the mineralocorticoid receptor, these antagonists can be employed in the treatment of conditions such as hypertension, heart failure, and certain endocrine disorders.
Additionally, the compound may also be utilized in other chemical synthesis processes where its specific chemical properties, such as the presence of the difluoro and sulfonyl chloride groups, can be exploited to create a variety of other organic compounds with potential applications in different industries.

InChI:InChI=1/C6H3ClF2O2S/c7-12(10,11)6-3-4(8)1-2-5(6)9/h1-3H

Upstream product

• 540-36-3 para-difluorobenzene 
• 367-30-6 2,5-difluoroaniline 

Downstream Products

• 904679-62-5 methyl 2-{[(2,5-difluorophenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 
• 1101821-02-6 C₆H₃F₂O₂S^(1-)*Na⁽¹⁺⁾ 
• 178049-79-1 isopropyl 2-methyl-3,6-difluorobenzenesulfonate 
• 1230476-86-4 isopropyl 2-ethyl-3,6-difluorobenzenesulfonate 
• 1195768-44-5 methyl 3-(2,5-difluorophenylsulfonamido)-4-fluorobenzoate 
• 1195768-24-1 3-(2,5-Difluorobenzenesulfonylamino)-2-fluorobenzoic acid methyl ester 
• 1195768-32-1 N-[3-[5-(2-chloro-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl]-2,5-difluorobenzenesulfonamide 
• 1195768-36-5 N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(4-morpholinyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,5-difluorobenzenesulfonamide 
• 1195768-39-8 N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(tetrahydro-2H-pyran-4-yl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,5-difluorobenzenesulfonamide 
• 1195768-58-1 C₁₄H₁₀ClF₂NO₄S 
• 1206836-18-1 N-(3-acetyl-2,4-difluoro-phenyl)-2,5-difluoro-benzenesulfonamide 
• 1206834-90-3 N-[2,4-difluoro-3-(4-pyridin-4-yl-1H-pyrazol-3-yl)-phenyl]-2,5-difluoro-benzenesulfonamide 
• 1206834-98-1 1-[2,4-difluoro-3-(4-pyridin-4-yl-1H-pyrazol-3-yl)-phenyl]-3-(4-trifluoromethyl-phenyl)-urea 
• 1206835-00-8 N-[3-(1-ethyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-2,4-difluoro-phenyl]-2,5-difluoro-benzenesulfonamide 

Relevant articles and documents

Thermodynamic characterization of new positive allosteric modulators binding to the glutamate receptor A2 ligand-binding domain: Combining experimental and computational methods unravels differences in driving forces

Positive allosteric modulation of the ionotropic glutamate receptor GluA2 presents a potential treatment of cognitive disorders, for example, Alzheimer's disease. In the present study, we describe the synthesis, pharmacology, and thermodynamic studies of a series of monofluoro-substituted 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides. Measurements of ligand binding by isothermal titration calorimetry (ITC) showed similar binding affinities for the modulator series at the GluA2 LBD but differences in the thermodynamic driving forces. Binding of 5c (7-F) and 6 (no-F) is enthalpy driven, and 5a (5-F) and 5b (6-F) are entropy driven. For 5d (8-F), both quantities were equal in size. Thermodynamic integration (TI) and one-step perturbation (OSP) were used to calculate the relative binding affinity of the modulators. The OSP calculations had a higher predictive power than those from TI, and combined with the shorter total simulation time, we found the OSP method to be more effective for this setup. Furthermore, from the molecular dynamics simulations, we extracted the enthalpies and entropies, and along with the ITC data, this suggested that the differences in binding free energies are largely explained by the direct ligand-surrounding enthalpies. Furthermore, we used the OSP setup to predict binding affinities for a series of polysubstituted fluorine compounds and monosubstituted methyl compounds and used these predictions to characterize the modulator binding pocket for this scaffold of positive allosteric modulators.

Nitromethylthiobenzene derivatives as inhibitors of aldose reductase

The invention concerns novel compound of general formula (1) in which: P, T1, T2, X and n are as defined in claim 1, their tautomeric forms, and their additive salts with pharmaceutically acceptable bases. The invention also concerns methods for preparing these compounds and their applications as medicines. These compounds inhibit the aldose reductase enzyme and can be used in the treatment or prevention of peripheral and autonomous neurological diabetic complications, renal and ocular disorders such as cataract and retinopathy.